← Altria overview

Altria vs Philip Morris International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Altria Group (MO)

Q3 2026
▲2▼2

Altria's mixed quarter: dividend and buybacks up, but vape setbacks and volume declines weigh

  • Dividend increase and doubled buybacks Altria raised its dividend 4.7% to $1.11 per share and doubled its stock buyback program to $2 billion, supporting a yield above 6% and returning more cash to shareholders.

    This is a new positive event that directly supports the stock price by increasing shareholder returns.

  • Defensive rotation and potential FDA rule on illicit tobacco Investors rotated into defensive stocks, and a proposed FDA rule requiring foreign tobacco importers to register could reduce illegal competition, helping Altria's pricing power and market position.

    This new development could improve Altria's competitive landscape and pricing ability.

  • Earnings miss, weak guidance, and cigarette volume declines Altria's Q2 earnings missed by $0.02, guidance disappointed, and cigarette volumes fell 4.5% then 10%, with Marlboro's market share slipping to 39.7%, reflecting ongoing demand weakness.

    These new negative results directly hurt investor sentiment and the stock price.

  • Vape setbacks: ZYN authorization, on! share loss, NJOY write-down Philip Morris's ZYN won the first FDA modified-risk authorization, pressuring Altria's on! whose share fell to 13.4%; NJOY ACE's import ban triggered a $1.30 billion write-down, hurting Altria's smoke-free ambitions.

    These new competitive and regulatory setbacks directly threaten Altria's reduced-risk product growth.

August 2026
▲2▼1

Altria's dividend rises even as cigarette volumes fall and smoke-free pivot stumbles

  • Dividend raised again, buyback doubled Altria lifted its quarterly dividend 4.7% to $1.11 per share, its 61st increase in 57 years, and doubled its buyback authorization to $2 billion. Returning $8 billion a year supports the stock by making the 6%-plus yield a reliable income stream.

    The dividend increase and bigger buyback are the period's clearest new positive for the share price.

  • Cigarette volumes fall 10%, Marlboro share slips Full-year domestic cigarette shipment volumes dropped 10.0% and Marlboro's retail share slipped to 39.7%, with discount brands now a third of the market. Falling volumes and shoppers trading down pressure revenue and profits, even though higher prices partly cushion the blow.

    This is the core new negative force: the shrinking cigarette business that funds everything else.

  • Smoke-free pivot stumbles: on! share falls, NJOY hit on! pouch shipments rose 17.6% but its category share fell 4.2 points to 13.4%, and NJOY ACE won't return due to an import ban, triggering a $1.30 billion write-down. The next-generation products meant to replace cigarettes are losing ground to rivals like ZYN.

    The smoke-free stumble is a real counterweight to the dividend story and a new negative for future growth.

  • FDA overhaul could speed vape and pouch approvals The Trump administration plans to streamline FDA review of flavored vapes and nicotine pouches, shortening years-long backlogs. Faster approvals would help Altria's NJOY and on! products reach shelves sooner, though public-health pushback could slow or block the change.

    A potential regulatory tailwind that directly addresses Altria's biggest growth obstacle.

Latest
▲2▼1

Altria's dividend rises even as cigarette volumes fall and smoke-free pivot stumbles

  • Dividend raised again, buyback doubled Altria lifted its quarterly dividend 4.7% to $1.11 per share, its 61st increase in 57 years, and doubled its buyback authorization to $2 billion. Returning $8 billion a year supports the stock by making the 6%-plus yield a reliable income stream.

    The dividend increase and bigger buyback are the period's clearest new positive for the share price.

  • Cigarette volumes fall 10%, Marlboro share slips Full-year domestic cigarette shipment volumes dropped 10.0% and Marlboro's retail share slipped to 39.7%, with discount brands now a third of the market. Falling volumes and shoppers trading down pressure revenue and profits, even though higher prices partly cushion the blow.

    This is the core new negative force: the shrinking cigarette business that funds everything else.

  • Smoke-free pivot stumbles: on! share falls, NJOY hit on! pouch shipments rose 17.6% but its category share fell 4.2 points to 13.4%, and NJOY ACE won't return due to an import ban, triggering a $1.30 billion write-down. The next-generation products meant to replace cigarettes are losing ground to rivals like ZYN.

    The smoke-free stumble is a real counterweight to the dividend story and a new negative for future growth.

  • FDA overhaul could speed vape and pouch approvals The Trump administration plans to streamline FDA review of flavored vapes and nicotine pouches, shortening years-long backlogs. Faster approvals would help Altria's NJOY and on! products reach shelves sooner, though public-health pushback could slow or block the change.

    A potential regulatory tailwind that directly addresses Altria's biggest growth obstacle.

July 2026
▲2▼2

Altria's Smoke-Free Hopes Hit by Q2 Miss and ZYN Rival Edge

  • Q2 earnings miss and soft guidance Altria's Q2 adjusted EPS of $1.48 missed estimates by 2 cents, and full-year guidance midpoint of $5.665 is below the $5.69 consensus. Cigarette shipment volume fell 4.5%, fueling worries about the core business. The stock dropped 9.3% on the news.

    This is the most recent and direct negative driver of MO's price, explaining the sharp sell-off.

  • ZYN gets first FDA modified-risk status for pouches The FDA authorized Philip Morris's ZYN as a modified-risk nicotine pouch, the first in the US. This gives PMI a regulatory edge over Altria's on! pouch, potentially slowing Altria's smoke-free growth and hurting its competitive position.

    This is a new competitive and regulatory setback that directly challenges Altria's smoke-free pivot.

  • FDA proposes foreign tobacco registration rule The FDA proposed requiring foreign tobacco manufacturers to register and list products, closing a loophole that let illegal foreign products flood the US. This would reduce competition for Altria, especially from illicit e-vapor, supporting its pricing power and market share.

    This is a new regulatory tailwind that could benefit Altria by curbing illegal competition.

  • Defensive rotation and dividend appeal With the Fed turning hawkish under new Chair Warsh, investors are rotating into defensive staples. Altria's ~6% dividend yield and 57-year streak of increases make it a top pick, as highlighted by Bank of America and Zacks. This supports demand for the stock.

    This is a new monetary and capital flow driver that boosts MO's attractiveness to income investors.

▲2▼2

Altria's Smoke-Free Hopes Hit by Q2 Miss and ZYN Rival Edge

  • Q2 earnings miss and soft guidance Altria's Q2 adjusted EPS of $1.48 missed estimates by 2 cents, and full-year guidance midpoint of $5.665 is below the $5.69 consensus. Cigarette shipment volume fell 4.5%, fueling worries about the core business. The stock dropped 9.3% on the news.

    This is the most recent and direct negative driver of MO's price, explaining the sharp sell-off.

  • ZYN gets first FDA modified-risk status for pouches The FDA authorized Philip Morris's ZYN as a modified-risk nicotine pouch, the first in the US. This gives PMI a regulatory edge over Altria's on! pouch, potentially slowing Altria's smoke-free growth and hurting its competitive position.

    This is a new competitive and regulatory setback that directly challenges Altria's smoke-free pivot.

  • FDA proposes foreign tobacco registration rule The FDA proposed requiring foreign tobacco manufacturers to register and list products, closing a loophole that let illegal foreign products flood the US. This would reduce competition for Altria, especially from illicit e-vapor, supporting its pricing power and market share.

    This is a new regulatory tailwind that could benefit Altria by curbing illegal competition.

  • Defensive rotation and dividend appeal With the Fed turning hawkish under new Chair Warsh, investors are rotating into defensive staples. Altria's ~6% dividend yield and 57-year streak of increases make it a top pick, as highlighted by Bank of America and Zacks. This supports demand for the stock.

    This is a new monetary and capital flow driver that boosts MO's attractiveness to income investors.

Philip Morris International Inc (PM)

Q3 2026
▲2▼1

PM gains on FDA Zyn win, revenue beat, but guidance cut pressures stock

  • FDA modified-risk status for Zyn The FDA granted modified-risk status to 20 Zyn variants, a category first. This boosts PM's smoke-free edge and could improve marketing and consumer acceptance.

    This regulatory win is a major new positive for PM's smoke-free strategy.

  • Strong Q2 revenue and EPS beat Q2 revenue rose 10.4% to $11.19 billion and adjusted EPS climbed 15.2%, beating estimates. This shows solid underlying business performance.

    The revenue and earnings beat is a key new positive driver for the stock.

  • EPS guidance cut and Q3 miss Full-year and Q3 EPS guidance was cut, and Q3 missed estimates. This pressured the stock despite other positives.

    The guidance cut is a significant new negative that weighed on PM's price.

  • Valuation stretched after rally After a 22.3% rally, PM trades at 27.2x earnings—above fair value and peers. This leaves little room for error if smoke-free growth slows.

    The high valuation is a new risk factor that could limit upside or increase downside.

August 2026
▲3

PM Gains on Zyn FDA Win, Capacity Expansion, and Dividend Hike

  • FDA Grants Zyn Modified Risk Status The FDA authorized 20 Zyn nicotine pouch variants as modified risk products, allowing PM to market them as less harmful than cigarettes. This first-of-its-kind regulatory win boosts investor confidence in PM's smoke-free strategy.

    This is a major regulatory catalyst that directly benefits PM's smoke-free portfolio and was not in earlier reports.

  • New Colorado Plant Boosts Smoke-Free Capacity PM opened a $1.2 billion manufacturing plant in Colorado, significantly increasing production capacity for smoke-free products. This supports future growth and meets rising demand for alternatives to cigarettes.

    This expansion is a new operational development that enhances PM's ability to scale its smoke-free business.

  • Dividend Increase and Altria Deal PM raised its dividend by 8.8% and secured a manufacturing deal with Altria. These moves signal confidence in cash flow and strengthen PM's production and distribution network.

    These are new capital allocation and partnership actions that reward shareholders and improve operational efficiency.

  • EPS Outlook Raised but Currency-Driven PM raised its 2026 EPS outlook, but the increase was due to favorable currency movements, not operational strength. The earlier guidance cut was also currency-related, highlighting that core business performance remains steady but not accelerating.

    This clarifies the nature of the EPS revision and provides a balanced view of the drivers behind the guidance change.

Latest
▲4

PM expands ZYN, raises dividend, sees faster FDA path

  • ZYN portfolio expansion PM added new ZYN strengths and launched FDA-authorized ZYN ULTRA, widening its smoke-free lineup. More choices for adult nicotine users help ZYN keep growing, which supports revenue and profit, and that pushes the stock up.

    Shows a concrete product expansion that drives future smoke-free revenue growth.

  • Dividend increase PM raised its quarterly dividend 8.8% to $1.60 per share, or $6.40 a year. A bigger cash payout rewards shareholders and signals confidence in future cash flow, making the stock more attractive to income investors and supporting its price.

    A direct shareholder-return event that boosts the stock's appeal.

  • Faster FDA approval pathway The Trump administration plans to speed FDA authorization for smoke-free nicotine products like pouches and vapes. A quicker, simpler path would help PM launch new products faster and widen its lead, lifting sales and the stock.

    A major regulatory tailwind that could accelerate PM's smoke-free growth.

  • Altria manufacturing deal PM's overseas affiliates will make combustible cigarettes for Altria's Philip Morris USA starting early 2027. This uses PM's factories more fully and adds fee income, a modest boost to profit and efficiency that helps the stock.

    A new supply agreement that improves factory utilization and adds income.

▲4

PM's smoke-free push gains regulatory wins and a China opening

  • EU regulatory appeal PM urged the EU to treat tobacco as a legal business ahead of tax and product reviews. If regulators soften rules, PM's cigarette and smoke-free sales face less pressure, lifting the stock. Shares rose 2.7% on the news.

    Shows PM actively shaping regulation that directly affects its sales and pricing power.

  • China patent deal speculation PM's R&D chief met China's tobacco regulator, sparking talk of a patent or licensing deal. A deal could open China's huge market for IQOS and ZYN, a major new growth source. No deal is confirmed yet.

    A potential new market is a big-picture growth driver not previously reported.

  • Raised 2026 EPS outlook PM raised its 2026 EPS forecast to $7.28–$7.43, citing currency only, and said adjusted EPS should rise about 11–13%. Higher expected earnings make the stock more attractive, though the raise is not from operations.

    Directly affects earnings expectations, a key driver of the stock price.

  • Q2 revenue beat PM's Q2 revenue of $11.19 billion beat estimates by 5.5%, the largest beat among 13 consumer stocks tracked. Strong sales show demand is holding up, supporting the stock even as peers' shares fell.

    Confirms underlying business strength, a core reason the stock is moving.

▲3

FDA ZYN Wins and $1.2B Plant Expand Smoke-Free Push; Currency Cut Repeats

  • FDA Grants ZYN First Modified Risk Status The FDA authorized ZYN nicotine pouches as modified risk products, letting PM market them as less harmful than cigarettes. This is a first for the category and gives PM a regulatory edge, boosting confidence in its smoke-free future and supporting the stock.

    This is a new regulatory win that directly strengthens PM's fastest-growing product line and investor sentiment.

  • $1.2 Billion Aurora ZYN Plant Opens PM opened a $1.2 billion Colorado campus to make ZYN pouches, doubling its original investment. The plant expands U.S. production and export capacity, positioning PM to meet rising demand and reinforcing its commitment to smoke-free growth.

    This new capital investment shows PM scaling up ZYN supply, which supports future revenue and market share.

  • FDA Authorizes 11 ZYN ULTRA Pouches The FDA cleared 11 ZYN ULTRA variants, including higher-strength 9mg and one 11mg option. This widens PM's product lineup and strengthens its lead in the fast-growing U.S. nicotine pouch market, supporting sales and pricing power.

    New product approvals expand PM's addressable market and competitive position in oral nicotine.

  • Q2 Beat but Guidance Cut on Currency PM beat Q2 estimates with strong cigarette volumes and smoke-free growth, but cut full-year EPS guidance due to a smaller currency benefit, not weak operations. The market initially rose on the operational strength, though the guidance cut still weighs on sentiment.

    This is the key financial update for the period, showing underlying demand is strong but reported earnings face a currency headwind.

July 2026
▲2▼1

FDA Zyn Win and Q2 Beat Drive PM, but Guidance Cut Weighs

  • FDA Grants Zyn Modified Risk Status The FDA authorized 20 Zyn nicotine pouch variants as modified risk products, allowing PM to market them as less harmful than cigarettes. This is a first for the category and gives PM a regulatory edge in smoke-free products, boosting investor confidence and the stock.

    This is a major new regulatory win that directly boosts PM's smoke-free strategy and stock price.

  • Q2 Revenue and Earnings Beat PM reported Q2 revenue of $11.19 billion, up 10.4% and beating estimates. Adjusted EPS rose 15.2% to $2.20, also above expectations. Organic sales grew 7.6%, driven by smoke-free and combustibles, showing strong underlying demand.

    The earnings beat confirms operational strength and supports the stock's positive reaction.

  • Full-Year EPS Guidance Cut PM lowered its full-year 2026 adjusted EPS guidance to $8.26-$8.41 from $8.36-$8.51, and its Q3 EPS forecast of $2.20-$2.25 missed the $2.42 estimate. This raised concerns about near-term profitability, causing the stock to slip 0.5% on the day.

    The guidance cut is a key counterweight that tempers the positive earnings and FDA news.

  • Valuation Debate After Rally After a 22.3% rally in 90 days, PM trades at 27.2 times earnings, above its fair value estimate and peers. While the Zyn FDA win is positive, much optimism may already be priced in, and any slowdown in smoke-free growth could pressure the stock.

    This highlights the risk that the stock may be overvalued after recent gains, providing a balanced view.

▲2▼1

FDA Zyn Win and Q2 Beat Drive PM, but Guidance Cut Weighs

  • FDA Grants Zyn Modified Risk Status The FDA authorized 20 Zyn nicotine pouch variants as modified risk products, allowing PM to market them as less harmful than cigarettes. This is a first for the category and gives PM a regulatory edge in smoke-free products, boosting investor confidence and the stock.

    This is a major new regulatory win that directly boosts PM's smoke-free strategy and stock price.

  • Q2 Revenue and Earnings Beat PM reported Q2 revenue of $11.19 billion, up 10.4% and beating estimates. Adjusted EPS rose 15.2% to $2.20, also above expectations. Organic sales grew 7.6%, driven by smoke-free and combustibles, showing strong underlying demand.

    The earnings beat confirms operational strength and supports the stock's positive reaction.

  • Full-Year EPS Guidance Cut PM lowered its full-year 2026 adjusted EPS guidance to $8.26-$8.41 from $8.36-$8.51, and its Q3 EPS forecast of $2.20-$2.25 missed the $2.42 estimate. This raised concerns about near-term profitability, causing the stock to slip 0.5% on the day.

    The guidance cut is a key counterweight that tempers the positive earnings and FDA news.

  • Valuation Debate After Rally After a 22.3% rally in 90 days, PM trades at 27.2 times earnings, above its fair value estimate and peers. While the Zyn FDA win is positive, much optimism may already be priced in, and any slowdown in smoke-free growth could pressure the stock.

    This highlights the risk that the stock may be overvalued after recent gains, providing a balanced view.